Pfs25-IMX313

Pfs25-IMX313 is an experimental transmission-blocking vaccine (TBV) candidate designed to combat *Plasmodium falciparum* malaria. The vaccine consists of the Pfs25 antigen—a protein expressed on the surface of the malaria parasite during its development in the mosquito midgut—fused to the IMX313 multimerization domain. IMX313 is a molecular adjuvant technology derived from the C4b-binding protein (C4bp) that causes the fused antigen to form heptameric nanoparticles. This multivalent presentation significantly enhances B-cell responses and the production of high-titer antibodies compared to monomeric Pfs25. When a mosquito ingests these antibodies during a blood meal from a vaccinated individual, the antibodies bind to Pfs25 on the parasite's surface, preventing further development within the mosquito and thereby breaking the cycle of transmission. The candidate has been evaluated in various delivery formats, including recombinant protein formulated with the Matrix-M adjuvant and viral vector systems such as ChAd63 and MVA.

Other names

ChAd63 Pfs25-IMX313ChAd-63 Pfs25-IMX313ChAd 63 Pfs25-IMX313MVA Pfs25-IMX313Pfs25-IMX313/Matrix-MPfs25-IMX313 protein-nanoparticlePfs-25-IMX313 protein-nanoparticlePfs 25-IMX313 protein-nanoparticle